Northern Ireland’s Department of Health has moved to allow year‑round prescribing of influenza antivirals under GP contracts. The statutory rule amends the 2004 prescribing regulations so that oseltamivir (Tamiflu) and zanamivir (Relenza) can be issued outside the usual flu season, with commencement from 1 May 2026. (niassembly.gov.uk)
In legal terms, the amendment alters Schedule 2 of the Health and Personal Social Services (General Medical Services Contracts) (Prescription of Drugs Etc) Regulations (Northern Ireland) 2004. It deletes specified sub‑paragraphs tied to seasonal notification: for oseltamivir, sub‑paragraph (a) in paragraphs (1) and (3); and for zanamivir, sub‑paragraph (a) in paragraph (1). (niassembly.gov.uk)
The Department’s explanatory material confirms that removing the notification requirement has the effect of permitting prescribing at any time of year, provided the remaining clinical conditions in column 2 of Schedule 2 are met. Those conditions continue to govern eligibility and use; only the seasonal ‘switch‑on’ has been taken out. (niassembly.gov.uk)
Assembly papers record the rule as SR 2026/72, laid on 1 April 2026 under the negative resolution procedure. The Assembly’s delegated legislation page notes the end of the statutory period on 18 May 2026, setting the parliamentary timetable around the change. (niassembly.gov.uk)
For prescribers, the practical change is straightforward: a Departmental or Chief Medical Officer notification that influenza is circulating is no longer a precondition for issuing oseltamivir or zanamivir on an HSC prescription. Clinicians must still document that the patient meets the Schedule 2 criteria and prescribe in line with local clinical guidance. (niassembly.gov.uk)
Community pharmacies should expect standard HSC prescriptions for these antivirals outside the traditional October–March period. Dispensing remains contingent on the prescriber’s adherence to Schedule 2 eligibility; the legislative gatekeeping has shifted from a seasonal administrative trigger to case‑by‑case clinical criteria. (niassembly.gov.uk)
The Department frames the move as a parallel to reforms in England, where the National Health Service (General Medical Services Contracts) (Prescription of Drugs etc.) (Amendment) Regulations 2025 came into force on 1 October 2025 to enable year‑round access for eligible patients. Northern Ireland’s instrument replicates that approach within its own 2004 framework. (niassembly.gov.uk)
The Explanatory Memorandum indicates no anticipated business or regulatory burden and no direct financial implications arising from the change. Because the patient‑eligibility rules remain intact, the volume effect is expected to reflect clinical demand outside the usual season rather than a broadening of indications. (niassembly.gov.uk)
By scale, GP prescribing in Northern Ireland accounts for over 45 million items annually with an ingredients cost above £501 million in 2023/24. Against that baseline, commissioners and practices should factor potential off‑season usage into routine monitoring, while continuing to prioritise appropriate antiviral stewardship. (health-ni.gov.uk)
Public health surveillance continues to track respiratory infection activity across the year. Under the previous regime, a CMO notification-based on epidemic thresholds-activated access; with this amendment, those thresholds inform clinical context rather than legal permission, aligning prescribing decisions more closely with patient‑level risk and test results. (niassembly.gov.uk)